UniProtKB/Swiss-Prot Q8WUM4: Variant p.Ala309Thr

Programmed cell death 6-interacting protein
Gene: PDCD6IP
Feedback?

Variant information Variant position:

309 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Alanine (A) to Threonine (T) at position 309 (A309T, p.Ala309Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from small size and hydrophobic (A) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs3792594 [ dbSNP | Ensembl ]

Sequence information Variant position:

309 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

868 The length of the canonical sequence.
Location on the sequence:

SRYDEYVNVKDFSDKINRAL A AAKKDNDFIYHDRVPDLKDL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SRYDEYVNVKDFSDKINRALAAAKKDNDFIYHDRVPDLKDL

Mouse                         SRYDEYVNVKDFSDKINRALTAAKKDNDFIYHDRVPDLKDL

Rat                           SRYDEYVNVKDFSDKINRALAAAKKDNDFIYHDRVPDLKDL

Xenopus laevis                SRYDEYVNVKDLADKINRALTAAKKDNDFIYHDRVPDLKDL

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 868	Programmed cell death 6-interacting protein
Domain	3 – 392	BRO1
Region	176 – 868	Interaction with EIAV p9
Region	176 – 503	Interaction with CHMP4A, CHMP4B and CHMP4C
Alternative sequence	272 – 868	Missing. In isoform 3.
Mutagenesis	317 – 317	F -> A. Diminishes rescue of PTAP-type L domain-deficient HIV-1 p6.
Mutagenesis	318 – 318	I -> A. Greatly diminishes rescue of PTAP-type L domain--deficient HIV-1 p6.
Mutagenesis	319 – 319	Y -> A. Greatly diminishes rescue of PTAP-type L domain-deficient HIV-1 p6.
Mutagenesis	319 – 319	Y -> F. No effect on rescue of PTAP-type L domain-deficient HIV-1 p6.
Helix	298 – 317

Literature citations
Molecular cloning of human ALG-2 interacting protein 1 (AIP1).
Li H.; Shioda T.; Isselbacher K.J.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANTS THR-309 AND LEU-730;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.